Floatz logo

Survaxm

Gliosarcoma

Roswell Park Cancer InstitutevaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

49 Active assets in the Gliosarcoma cohort.

Asset / SponsorPhaseRating
Cediranib
Northwestern University
Phase 2BBB
Temsirolimus
National Cancer Institute (NCI)
Phase 2BBB
Sorafenib
University Hospital, Geneva
Phase 2BB
Gefetinib
National Cancer Institute (NCI)
Phase 2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Survaxm is also rated in:

glioblastomaDormant
CCC
Indicative ·
55 / 100
View asset →
lung neuroendocrine neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →